NAD+ and NMN: The Longevity Molecule Under the Microscope
A critical examination of NAD+ precursors NMN and NR: what the human clinical trials actually show, optimal dosing, and realistic expectations.
Lead Science Writer · Peer-Reviewed Sources
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell, essential for energy metabolism, DNA repair, and cellular signaling. NAD+ levels decline with age, and this decline is now considered a hallmark of aging.
The NAD+ Decline
Multiple studies confirm that tissue NAD+ levels decrease by approximately 50% between ages 40 and 60. This decline correlates with:
- Reduced mitochondrial function
- Impaired DNA repair capacity
- Increased cellular senescence
- Decreased sirtuin activity
NMN vs NR: The Precursor Debate
NMN (Nicotinamide Mononucleotide): Direct precursor to NAD+. Requires the Slc12a8 transporter for cellular uptake. Molecular weight 334 Da.
NR (Nicotinamide Riboside): Converted to NMN intracellularly, then to NAD+. Uses equilibrative nucleoside transporters. Molecular weight 255 Da.
Both effectively raise blood NAD+ levels. The practical difference in humans remains unclear despite fierce marketing claims from both camps.
Human Clinical Trial Evidence
NMN Trials
- Yi et al. (2023): 250mg NMN daily for 60 days increased blood NAD+ by 38% in middle-aged adults
- Katayoshi et al. (2023): 250mg improved sleep quality and reduced drowsiness in older adults
- Liao et al. (2021): 600-1200mg improved aerobic capacity in amateur runners after 6 weeks
NR Trials
- Martens et al. (2018): 1000mg NR (as Niagen) for 6 weeks reduced blood pressure by 2-4 mmHg
- Elhassan et al. (2019): 1000mg NR increased skeletal muscle NAD+ metabolome in older men
What the Evidence Does NOT Show
Honesty requires noting significant limitations:
- No long-term (>1 year) human trial data exists
- No human study has demonstrated lifespan extension
- Cognitive benefits seen in mice have not reliably translated to humans
- Optimal dosing remains uncertain
- Individual response varies significantly
Dosing Guidance
Based on available human data:
- NMN: 250-500mg daily appears sufficient to raise NAD+ levels
- NR: 300-1000mg daily (most trials use 500-1000mg)
- Timing: Morning administration preferred (NAD+ follows circadian rhythms)
- Duration: Effects on blood NAD+ measurable within 2 weeks
Evidence Strength Assessment
| Claim | Evidence Level |
|---|---|
| Raises blood NAD+ levels | Strong (multiple RCTs) |
| Improves exercise capacity | Moderate (small trials) |
| Reduces blood pressure | Moderate (one well-designed RCT) |
| Improves sleep quality | Emerging (one trial) |
| Extends human lifespan | No evidence |
| Reverses aging | No evidence |
Key Takeaways
- NAD+ decline with age is real and well-documented
- Both NMN and NR effectively raise NAD+ levels in humans
- Benefits beyond biomarker changes are still being established
- Marketing claims far outpace the actual evidence
- Reasonable as part of a longevity-oriented supplement stack, but expectations should be calibrated to the data
Sources: Yi et al. (2023) Cell Metab, Martens et al. (2018) Nat Commun, Elhassan et al. (2019) Cell Reports, Yoshino et al. (2021) Science